Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
Clinical Trials
13
4 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
4
30.8%
Completed
7
53.9%
Recruiting
2
15.4%
No approval data available
- Candel Therapeutics is advancing its lead candidate CAN-2409 toward a biologics license application (BLA) submission expected in the fourth quarter, with management citing "meaningful execution" toward the filing. - The clinical-stage immuno-oncology company is targeting its first commercial product launch in 2027, positioning regulatory progress as a key catalyst. - Analysts hold a consensus "Moderate Buy" rating on the stock, with HC Wainwright reaffirming a Buy rating and $23 price target while forecasting EPS of $0.69 in fiscal 2028 and $1.41 in fiscal 2029. - Candel reported a second-quarter loss of $0.52 per share, missing consensus estimates of $0.27, reflecting continued cash burn for the clinical-stage biotechnology company.
- The global oncolytic virus therapy market is projected to grow from USD 21.54 million in 2025 to USD 223.5 million by 2035, at a CAGR of 26.36% during 2026–2035. - Oncolytic viruses selectively infect and destroy cancer cells while stimulating systemic anti-tumor immune responses, transforming "cold" tumors into "hot" ones. - A robust clinical pipeline, including cretostimogene grenadenorepvec, CAN-2409, RP1, and Olvi-Vec, is advancing across melanoma, bladder, lung, and other solid tumors. - Recent regulatory milestones, including FDA accelerated approval of TUDRIQEV (RP1) for advanced melanoma, underscore growing momentum in the field.
- The oncolytic virus therapy landscape has expanded steadily over the past decade, with over 100 companies worldwide pursuing clinical or preclinical programs developing 110+ oncolytic virus drugs. - Key market drivers include growing cancer incidence in hard-to-treat solid tumors, increasing understanding of cancer biology, advancements in viral engineering, and rising adoption of personalized medicine approaches. - Leading companies such as Candel Therapeutics, Oncolytics Biotech, and CG Oncology are advancing promising therapies like CAN-2409, Pelareorep, and CG0070 through Phase III clinical trials. - Recent developments include innovative combination approaches, with Imugene and JW Therapeutics collaborating on CF33-CD19 with CAR-T therapy, and multiple FDA designations granted including Fast Track and RMAT status.
- Candel Therapeutics announced interim data from a phase 1b clinical trial of CAN-3110, an engineered herpes virus therapy for recurrent glioblastoma, with results published in Science Translational Medicine. - The therapy uses a modified herpes virus to selectively target and kill brain tumor cells while triggering an inflammatory response that activates the patient's immune system against the cancer. - Patient Kyle Donahue, diagnosed with glioblastoma in 2021 and given months to live, has become a five-year survivor after participating in the clinical trial at Brigham and Women's Hospital. - The treatment involves a multi-day protocol including MRI imaging, chemotherapy infusion, and surgical administration of the viral therapy directly into the brain tumor.
- Candel Therapeutics' CAN-2409 demonstrated a 30% reduction in prostate cancer recurrence risk in a completed pivotal phase 3 trial under FDA Special Protocol Assessment. - The company's viral immunotherapy platform includes CAN-3110 showing promising survival outcomes in recurrent glioblastoma with durable responses reported. - FDA has granted multiple designations including RMAT for prostate cancer and Fast Track status for several indications across both lead programs. - Candel maintains strong financial position with $87 million cash and $130 million term loan facility to fund operations into first quarter 2027.
- Candel Therapeutics announced promising interim data from its phase 1b trial of CAN-3110 in recurrent glioblastoma, with one patient achieving complete pathological response. - A Science Translational Medicine publication revealed that CAN-3110 transforms the tumor microenvironment by replacing tumor cells with immune cells, though this appears as disease progression on MRI. - Updated survival data showed median overall survival of 11.8-12.0 months across treatment arms, with some patients surviving over 59 months after treatment. - The company plans to design a phase 2 clinical trial based on these encouraging results and evidence of immune activation in the tumor microenvironment.
- Candel Therapeutics secured a five-year, $130 million term loan facility with Trinity Capital, drawing $50 million at closing with access to an additional $80 million based on milestones. - The funding will enable initiation of a pivotal phase 3 clinical trial of CAN-2409 in non-small cell lung cancer in Q2 2026 and support potential commercial launch in early localized prostate cancer. - The company has prioritized its portfolio to focus CAN-2409 development on prostate cancer and NSCLC, seeking external partnerships for pancreatic cancer development. - Combined with existing cash of $87.2 million as of September 30, 2025, the facility strengthens Candel's financial position through expected BLA submission for prostate cancer in Q4 2026.
- A phase 2a trial of CAN-2409 viral immunotherapy showed median overall survival of 24.5 months in 46 patients with advanced NSCLC who failed immune checkpoint inhibitor therapy. - Patients with non-squamous histology demonstrated significantly longer survival than those with squamous histology (25.4 vs. 13.3 months), linked to increased cytotoxic T-cell infiltration. - The treatment triggered systemic immune activation with abscopal responses in 69% of patients with multiple lesions, indicating robust anti-tumor effects beyond the injection site. - CAN-2409 maintained a favorable safety profile throughout extended follow-up, supporting advancement to larger randomized controlled trials.
- Candel Therapeutics has appointed Charles Schoch as permanent Chief Financial Officer, transitioning from his interim role held since January 2024. - Schoch led the company through a successful $86 million capital raise following positive phase 3 results for CAN-2409 in localized prostate cancer in December 2024. - The appointment comes as Candel prepares for its Biologics License Application submission for CAN-2409 in localized prostate cancer and advances its multimodal immunotherapy pipeline.
- Candel Therapeutics appointed Dr. Maha Radhakrishnan to its Board of Directors, bringing over 20 years of product development and commercialization experience from major biotech and pharmaceutical companies. - The appointment strategically positions Candel as it prepares for its Biologics License Application submission for CAN-2409 in intermediate-to-high-risk prostate cancer, anticipated in Q4 2026. - Dr. Radhakrishnan's expertise will support Candel's multimodal immunotherapy approach across multiple cancer indications, including treatments that have received FDA Fast Track and RMAT designations.
